Louisa Smith
Vice President, Investor Relations
Replay available
TELA Bio, Inc. (NASDAQ: TELA) Q1 2026 earnings conference call, held 2026-05-12. Replay captured from the company's public earnings webcast.

Vice President, Investor Relations
Chief Executive Officer
President
Chief Operating Officer and Chief Financial Officer
Senior Vice President, Strategic Operations and Marketing
Analyst, Canaccord Genuity
Analyst, Jefferies
Good day, everyone, and welcome to TELA's first quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to turn the call over to Louisa Smith. Please go ahead. Thank you, Carmen, and good afternoon, everyone. Earlier today, Telebio released financial results for the first quarter ended March 31st, 2026. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, Chief Executive Officer, Jeff Blizzard, President, Roberto Cuca, Chief Operating Officer and Chief Financial Officer, and Jim Hagan, SVP of Strategic Operations and Marketing. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. With that, I'll now turn the call over to Tony. Thank you, Louisa. Good afternoon, and thank you for joini...